NCT04823611View on ClinicalTrials.gov

A Study of AZD8233 in Participants With Dyslipidemia.

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

87

Participants

Timeline

Start Date

January 20, 2021

Primary Completion Date

September 10, 2022

Study Completion Date

September 10, 2022

Conditions
Dyslipidemia
Interventions
DRUG

Part A:Placebo

Placebo solution

DRUG

Part A:AZD8233

PCSK9-targeted ASO for the reduction of circulating levels of LDL-C.

DRUG

Part B:Placebo

Placebo solution

DRUG

Part B:AZD8233

PCSK9-targeted ASO for the reduction of circulating levels of LDL-C.

DRUG

Part C: Placebo

Placebo solution

DRUG

Part C: AZD8233

PCSK9-targeted ASO for the reduction of circulating levels of LDL-C.

Trial Locations (7)

1010041

Research Site, Chiyoda-ku

1040031

Research Site, Chūōku

103-0027

Research Site, Chūōku

104-0031

Research Site, Chūōku

530-0001

Research Site, Osaka

160-0008

Research Site, Shinjuku-ku

565-0853

Research Site, Suita-shi

Sponsors

Lead Sponsor

AstraZeneca
All Listed Sponsors
lead

AstraZeneca

INDUSTRY